| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | Felzartamab (MOR202) - (IGNAZ) | Immunoglobulin A Nephropathy (IgAN) - Berger's disease | Phase 2 | Ongoing | Intravenous | #N/A |
| Novartis AG | FCR001 - (FREEDOM-3) | Scleroderma | Phase 2 | Clinical Pause | Intravenous | Immunology |
| Novartis AG | ECF843 | Dry Eye Disease | Phase 2 | Trial Discontinued | topical ophthalmic | Opthalmic |
| Novartis AG | Atrasentan - (AFFINITY) | Chronic kidney disease | Phase 2 | Ongoing | Oral | N/A |
| Novartis AG | MOR208 + idelalisib (COSMOS) | Chronic Lymphocytic Leukemia | Phase 2 | Ongoing | Intravenous | Oncology |
| Novavax Inc. | NVX-CoV2373 | COVID-19 vaccine | BLA Filing | Ongoing | Intramuscular | COVID-19 |
| Novavax Inc. | 2019nCoV-415 (Adjuvanted 2024-2025 Formula) - (SHIELD) | COVID-19 Vaccine | Phase 3 | Data Released | Intramuscular injection | COVID-19 |
| Novavax Inc. | COVID-19 vaccine (NVX-CoV2705) | COVID-19-Influenza Combination (CIC) 2024-2025 | Phase 3 | Ongoing | Intramuscular | COVID-19 |